Marker Therapeutics (MRKR) Change in Interest Receivables (2018 - 2025)
Marker Therapeutics (MRKR) reported Change in Interest Receivables of -$9182.0 for Q3 2025, up 99.47% year-over-year from -$4603.1 in Q3 2024, and up 98.83% quarter-over-quarter from -$784430.0 in Q2 2025.
Marker Therapeutics (MRKR) Change in Interest Receivables (2018 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has 8 years of Change in Interest Receivables data on file, last reported at -$9182.0 in Q3 2025.
- Change in Interest Receivables for Q3 2025 came in at -$9182.0, up 99.47% year-over-year; the trailing twelve-month figure through Sep 2025 was $920743.0 (up 39.28% YoY), and the FY2024 annual result was $1.3 million, up 195.98% from the prior year.
- Change in Interest Receivables grew to -$9182.0 in Q3 2025 per MRKR's latest filing, from -$784430.0 in the prior quarter.
- Over five years, Change in Interest Receivables peaked at $1.6 million in Q4 2024 and troughed at -$1.7 million in Q3 2024.
- A 5-year average of $34978.6 and a median of $1948.0 in 2022 frame the typical range for Change in Interest Receivables.
- The sharpest annual moves came in 2022 and 2023: Change in Interest Receivables surged 12016516.67% in 2022, then plunged 67816.53% in 2023.
- A 5-year view of Change in Interest Receivables shows it stood at -$6.0 in 2021, then surged by 12016516.67% to $720985.0 in 2022, then jumped by 31.0% to $944502.0 in 2023, then jumped by 69.64% to $1.6 million in 2024, then tumbled by 100.57% to -$9182.0 in 2025.
- Business Quant data shows MRKR's Change in Interest Receivables at -$9182.0 in Q3 2025, -$784430.0 in Q2 2025, and $112062.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -9,182.00 |
| Jun 30, 2025 | -784,430.00 |
| Mar 31, 2025 | 112,062.00 |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | 638,685.00 |
| Mar 31, 2024 | 823,647.00 |
| Dec 31, 2023 | 944,502.00 |
| Sep 30, 2023 | -1.66 Mn |
| Jun 30, 2023 | 663,214.00 |
| Mar 31, 2023 | -1.32 Mn |
| Dec 31, 2022 | 720,985.00 |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 625,444.00 |
| Mar 31, 2022 | 1,948.00 |
| Dec 31, 2021 | -6.00 |
| Sep 30, 2021 | -43.00 |
| Jun 30, 2021 | -1.00 Mn |
| Mar 31, 2021 | 308.00 |
| Dec 31, 2020 | 424.00 |